Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is one of the most common fatal malignancies and the main cause of cancer-related deaths. The multitarget tyrosine kinase inhibitors (TKIs) sorafenib and regorafenib are systemic therapeutic drugs approved for the treatment of HCC. Here, we found that sorafenib and reg...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shun, Wang, Yixin, Cao, Yifan, Wu, Jin, Zhang, Zubin, Ren, Haigang, Xu, Xiaohui, Kaznacheyeva, Elena, Li, Qing, Wang, Guanghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967359/
https://www.ncbi.nlm.nih.gov/pubmed/35370635
http://dx.doi.org/10.3389/fphar.2022.851832

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967359/
https://www.ncbi.nlm.nih.gov/pubmed/35370635
http://dx.doi.org/10.3389/fphar.2022.851832

Ejemplares similares